We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+36.31%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$890M
AUM Growth
+$233M
Cap. Flow
+$63.4M
Cap. Flow %
7.12%
Top 10 Hldgs %
74.13%
Holding
34
New
2
Increased
15
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$40.6M
2
PCVX icon
Vaxcyte
PCVX
+$38.6M
3
VERA icon
Vera Therapeutics
VERA
+$23.7M
4
MRUS
Merus
MRUS
+$23M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$15.9M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$47.4M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$20.5M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$10.1M
5
RNAM
Avidity Biosciences
RNAM
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
26
DBV Technologies
DBVT
$807M
$176K 0.02%
9,269
– –
ABOS icon
27
Acumen Pharmaceuticals
ABOS
$154M
– –
-400,000
Closed -$1.62M
ACRS icon
28
Aclaris Therapeutics
ACRS
$730M
– –
-635,000
Closed -$5.14M
ALLK
29
DELISTED
Allakos
ALLK
– –
-1,900,000
Closed -$8.46M
ENTA icon
30
Enanta Pharmaceuticals
ENTA
$372M
– –
-217,253
Closed -$8.79M
RNAM
31
DELISTED
Avidity Biosciences
RNAM
– –
-590,705
Closed -$9.07M
RZLT icon
32
Rezolute
RZLT
$480M
– –
-898,267
Closed -$1.72M
BLU
33
DELISTED
BELLUS Health Inc.
BLU
– –
-6,579,359
Closed -$47.4M
RXDX
34
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-127,156
Closed -$13.6M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Commodore Capital held 34 positions worth $890M, up 35% from $657M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Commodore Capital deployed $63.4M of net new capital in Q2 2023, opening 2 new positions and adding to 15 existing holdings. Its largest new stake was IDEAYA Biosciences: 775,000 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ambrx Biopharma Inc, an estimated $20.5M trimmed.

  • Commodore Capital's largest Q2 2023 buy was IDEAYA Biosciences: 775,000 shares worth $18.2M.
  • Commodore Capital added most to Akero Therapeutics in Q2 2023, an estimated $40.6M increase.
  • Commodore Capital's biggest Q2 2023 reduction was Ambrx Biopharma Inc, cutting an estimated $20.5M.
  • Commodore Capital fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $47.4M.
  • Commodore Capital's ten largest holdings make up 74% of its $890M portfolio in Q2 2023.
  • Commodore Capital opened 2 new positions and closed 8 in Q2 2023.
  • Commodore Capital's portfolio value rose 35% quarter-over-quarter to $890M.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.